vs
Side-by-side financial comparison of Global-E Online Ltd. (GLBE) and HALOZYME THERAPEUTICS, INC. (HALO). Click either name above to swap in a different company.
Global-E Online Ltd. is the larger business by last-quarter revenue ($625.5M vs $451.8M, roughly 1.4× HALOZYME THERAPEUTICS, INC.). Global-E Online Ltd. runs the higher net margin — 0.9% vs -31.3%, a 32.3% gap on every dollar of revenue.
Global-E Online Ltd. operates a leading cross-border e-commerce enablement platform that helps direct-to-consumer brands and retail enterprises expand their international sales reach. It offers end-to-end services including localized checkout, payment processing, customs clearance, logistics coordination, and duty calculation, serving clients across North America, Europe, and the Asia-Pacific region.
Halozyme Therapeutics, Inc. is an American biotechnology company. It develops oncology therapies designed to target the tumor microenvironment.
GLBE vs HALO — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $625.5M | $451.8M |
| Net Profit | $5.8M | $-141.6M |
| Gross Margin | 45.0% | 82.6% |
| Operating Margin | 1.3% | -20.6% |
| Net Margin | 0.9% | -31.3% |
| Revenue YoY | — | 51.6% |
| Net Profit YoY | — | -203.3% |
| EPS (diluted) | — | $-1.13 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $451.8M | ||
| Q3 25 | $625.5M | $354.3M | ||
| Q2 25 | $404.8M | $325.7M | ||
| Q1 25 | $189.9M | $264.9M | ||
| Q4 24 | — | $298.0M | ||
| Q3 24 | $489.9M | $290.1M | ||
| Q2 24 | $313.9M | $231.4M | ||
| Q1 24 | $145.9M | $195.9M |
| Q4 25 | — | $-141.6M | ||
| Q3 25 | $5.8M | $175.2M | ||
| Q2 25 | $-7.4M | $165.2M | ||
| Q1 25 | — | $118.1M | ||
| Q4 24 | — | $137.0M | ||
| Q3 24 | $-77.1M | $137.0M | ||
| Q2 24 | $-54.5M | $93.2M | ||
| Q1 24 | — | $76.8M |
| Q4 25 | — | 82.6% | ||
| Q3 25 | 45.0% | 84.4% | ||
| Q2 25 | 44.9% | 85.8% | ||
| Q1 25 | 44.3% | 81.7% | ||
| Q4 24 | — | 85.9% | ||
| Q3 24 | 45.1% | 83.0% | ||
| Q2 24 | 44.8% | 82.9% | ||
| Q1 24 | 43.4% | 85.5% |
| Q4 25 | — | -20.6% | ||
| Q3 25 | 1.3% | 61.5% | ||
| Q2 25 | -2.1% | 62.2% | ||
| Q1 25 | -10.1% | 53.4% | ||
| Q4 24 | — | 58.9% | ||
| Q3 24 | -14.9% | 56.3% | ||
| Q2 24 | -16.6% | 50.7% | ||
| Q1 24 | -20.1% | 48.8% |
| Q4 25 | — | -31.3% | ||
| Q3 25 | 0.9% | 49.5% | ||
| Q2 25 | -1.8% | 50.7% | ||
| Q1 25 | — | 44.6% | ||
| Q4 24 | — | 46.0% | ||
| Q3 24 | -15.7% | 47.2% | ||
| Q2 24 | -17.4% | 40.3% | ||
| Q1 24 | — | 39.2% |
| Q4 25 | — | $-1.13 | ||
| Q3 25 | — | $1.43 | ||
| Q2 25 | — | $1.33 | ||
| Q1 25 | — | $0.93 | ||
| Q4 24 | — | $1.06 | ||
| Q3 24 | — | $1.05 | ||
| Q2 24 | — | $0.72 | ||
| Q1 24 | — | $0.60 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $251.4M | $133.8M |
| Total DebtLower is stronger | — | $2.1B |
| Stockholders' EquityBook value | $933.0M | $48.8M |
| Total Assets | $1.3B | $2.5B |
| Debt / EquityLower = less leverage | — | 43.89× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $133.8M | ||
| Q3 25 | $251.4M | $419.7M | ||
| Q2 25 | $205.2M | $61.9M | ||
| Q1 25 | $207.7M | $176.3M | ||
| Q4 24 | — | $115.8M | ||
| Q3 24 | $207.3M | $154.3M | ||
| Q2 24 | $229.8M | $187.9M | ||
| Q1 24 | $181.9M | $164.6M |
| Q4 25 | — | $2.1B | ||
| Q3 25 | — | $1.5B | ||
| Q2 25 | — | $1.5B | ||
| Q1 25 | — | $1.5B | ||
| Q4 24 | — | $1.5B | ||
| Q3 24 | — | $1.5B | ||
| Q2 24 | — | $1.5B | ||
| Q1 24 | — | $1.5B |
| Q4 25 | — | $48.8M | ||
| Q3 25 | $933.0M | $503.9M | ||
| Q2 25 | $909.1M | $332.7M | ||
| Q1 25 | $884.3M | $482.3M | ||
| Q4 24 | — | $363.8M | ||
| Q3 24 | $869.4M | $452.7M | ||
| Q2 24 | $878.7M | $289.4M | ||
| Q1 24 | $886.9M | $177.8M |
| Q4 25 | — | $2.5B | ||
| Q3 25 | $1.3B | $2.2B | ||
| Q2 25 | $1.2B | $2.1B | ||
| Q1 25 | $1.2B | $2.2B | ||
| Q4 24 | — | $2.1B | ||
| Q3 24 | $1.2B | $2.1B | ||
| Q2 24 | $1.1B | $2.0B | ||
| Q1 24 | $1.1B | $1.8B |
| Q4 25 | — | 43.89× | ||
| Q3 25 | — | 3.00× | ||
| Q2 25 | — | 4.54× | ||
| Q1 25 | — | 3.13× | ||
| Q4 24 | — | 4.14× | ||
| Q3 24 | — | 3.32× | ||
| Q2 24 | — | 5.19× | ||
| Q1 24 | — | 8.44× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $219.0M |
| Free Cash FlowOCF − Capex | — | $217.6M |
| FCF MarginFCF / Revenue | — | 48.2% |
| Capex IntensityCapex / Revenue | — | 0.3% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $644.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $219.0M | ||
| Q3 25 | — | $178.6M | ||
| Q2 25 | — | $99.7M | ||
| Q1 25 | — | $154.2M | ||
| Q4 24 | — | $178.5M | ||
| Q3 24 | — | $115.4M | ||
| Q2 24 | — | $55.8M | ||
| Q1 24 | — | $129.4M |
| Q4 25 | — | $217.6M | ||
| Q3 25 | — | $175.6M | ||
| Q2 25 | — | $98.1M | ||
| Q1 25 | — | $153.3M | ||
| Q4 24 | — | $175.4M | ||
| Q3 24 | — | $113.9M | ||
| Q2 24 | — | $53.2M | ||
| Q1 24 | — | $125.9M |
| Q4 25 | — | 48.2% | ||
| Q3 25 | — | 49.6% | ||
| Q2 25 | — | 30.1% | ||
| Q1 25 | — | 57.9% | ||
| Q4 24 | — | 58.9% | ||
| Q3 24 | — | 39.3% | ||
| Q2 24 | — | 23.0% | ||
| Q1 24 | — | 64.3% |
| Q4 25 | — | 0.3% | ||
| Q3 25 | — | 0.9% | ||
| Q2 25 | — | 0.5% | ||
| Q1 25 | — | 0.4% | ||
| Q4 24 | — | 1.0% | ||
| Q3 24 | — | 0.5% | ||
| Q2 24 | — | 1.1% | ||
| Q1 24 | — | 1.8% |
| Q4 25 | — | — | ||
| Q3 25 | — | 1.02× | ||
| Q2 25 | — | 0.60× | ||
| Q1 25 | — | 1.31× | ||
| Q4 24 | — | 1.30× | ||
| Q3 24 | — | 0.84× | ||
| Q2 24 | — | 0.60× | ||
| Q1 24 | — | 1.68× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GLBE
Segment breakdown not available.
HALO
| Royalty | $258.0M | 57% |
| Products | $122.7M | 27% |
| Proprietary Products Sales | $59.6M | 13% |
| Device Partnered Products | $12.9M | 3% |
